JAZZ News and Press, Jazz Pharmaceuticals plc From 01/18/24

2024-01-18 11:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

2024-01-11 11:31:29 ET Summary Avadel Pharma's launch of its product LUMRYZ is expected to drive the company's stock performance. LUMRYZ appears to have momentum and is differentiated from current narcolepsy treatments. The potential revenue for Avadel from LUMRYZ could ultima...

2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...

2023-12-21 16:25:06 ET Jazz Pharmaceuticals ( NASDAQ: JAZZ ) on Thursday said a mid-stage trial of its investigational therapy for the treatment of post-traumatic stress disorder (PTSD) failed to meet the main goal of the study, sending its shares falling as much as ~6% aft...

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder PR Newswire DUBLIN , Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from ...

2023-12-21 07:24:53 ET Summary Jazz Pharmaceuticals' market valuation is fairly conservative overlooking its promising potential. Zanidatamab's Phase 2a success boosts Jazz's oncology market potential. Despite challenges, Jazz's strategic positioning and conservative market va...

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42 nd...

2023-12-15 15:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-08 15:14:26 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals PLC (JAZZ) Q3 2023 Earnings Call Transcript Jazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call Presentation Jazz Pharma: Playing The High Notes With Xywav UBS lowers Jazz to neut...

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer PR Newswire First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant...